CYP2C8, CYP2C9 and CYP2C Cluster
Also known as: 2C8/2C9
Use
This test is used to assess the genetic risk of abnormal drug metabolism for drugs metabolized by enzymes coded by CYP2C8, CYP2C9, and the 2C cluster variant (rs12777823). It may aid in drug selection and dose planning for such drugs, with emphasis on personalized medicine to optimize therapeutic outcomes and minimize adverse reactions based on individual genetic makeup.
Special Instructions
Informed consent for genetic testing is required for patients in New York. Counseling and informed consent are recommended with this genetic test. Consent forms are available online.
Limitations
The test will only detect targeted CYP2C8, CYP2C9, and CYP2C cluster variants and may not detect rare sequence variations. Diagnostic errors can occur due to these variations. Risk of therapeutic failure or adverse reactions with CYP2C8 or CYP2C9 substrates may be influenced by genetic and non-genetic factors not detected by this panel. The test does not replace the need for therapeutic drug or clinical monitoring.
New York Approved
Methodology
PCR-based (Fluorescence Monitoring)
Biomarkers
LOINC Codes
- 79716-7
- 66746-9
- 78972-7
- 46724-1
- 50398-7
- 81259-4
- 101785-4
- 11526-1
Result Turnaround Time
5-10 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
3 mL
Minimum Volume
1 mL
Container
Lavender (EDTA), pink (K2EDTA), or yellow (ACD solution A or B).
Storage Instructions
Preferred transport temperature is refrigerated.
Causes for Rejection
Plasma or serum. Specimens collected in sodium heparin or lithium heparin. Frozen specimens in glass collection tubes.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 3 days |
| Refrigerated | 1 week |
| Frozen | 1 month |